Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris

This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.

Inclusion Criteria:

• Males and females, ages 13 and up, exhibiting high levels of facial P. acnes
• Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria:

• Acne conglobata, acne fulminans, or secondary acne (chlorine, drug-induced acne, etc.)
• Active facial cysts